Interleukin 28B Gene Variation at rs12979860 Determines Early Viral Kinetics During Treatment in Patients Carrying Genotypes 2 or 3 of Hepatitis C Virus
Interleukin 28B Gene Variation at rs12979860 Determines Early Viral Kinetics During Treatment in Patients Carrying Genotypes 2 or 3 of Hepatitis C Virus
复制标题
DOI：
10.1093/infdis/jir193
复制
发表时间：
2011-06-15
影响因子：
6.4
通讯作者：
Hellstrand, Kristoffer
中科院分区：
文献类型：
--
作者：
Lindh, Magnus;Lagging, Martin;Hellstrand, Kristoffer
白细胞介素28B(干扰素lambda 3)基因(IL28B)上游单核苷酸多态性显著影响1型丙型肝炎病毒(HCV)携带者的治疗效果。在接受干扰素-利巴韦林治疗12周或24周的2型或3型丙型肝炎患者(n=341)中，我们发现rs12979860显著决定了病毒消除的第一阶段(P<；.001)。在治疗24周的患者中，rs12979860还预测了持续病毒学应答率(P=0.02)，特别是在基线水平较高的丙型肝炎病毒RNA水平(P=0.002)或45岁以上(P=0.01)的患者中。携带CCrs12979860的患者比携带Ctrs1297986或Ttrs1297986的患者有更高的基线丙型肝炎病毒RNA水平(P<；.001)，在治疗12周后，没有更多的持续病毒学应答。结果表明，IL28B基因检测可以确定携带2或3型的患者，这些患者可以从扩大治疗中受益。
Single-nucleotide polymorphisms upstream of the interleukin 28B (interferon lambda 3) gene (IL28B) strongly influence treatment efficacy in patients carrying hepatitis C virus (HCV) of genotype 1. In patients receiving 12 or 24 weeks of interferon-ribavirin therapy for infection with genotype 2 or 3 (n = 341), we found that rs12979860 strikingly determined the first phase of viral elimination (P < .001). In patients treated for 24 weeks, rs12979860 also predicted the rate of sustained virologic response (P = .02), especially among those with high baseline HCV RNA levels (P = .002) or older than 45 years (P = .01). Patients carrying CCrs12979860 had higher baseline HCV RNA levels (P < .001) and did not, when treated for 12 weeks, achieve sustained virologic response more often than those carrying CTrs1297986 or TTrs1297986. The results indicate that IL28B gene testing may identify patients carrying genotype 2 or 3 who could benefit from extended treatment.